Abstract Details

Title Patient Preferences for Attributes of Advanced Migraine Prevention Medications: Findings from a Discrete Choice Experiment

Topic Headache

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 2-004

Objective

To assess the relative importance of 5 attributes in the choice of preventive migraine treatment from the patient perspective.

Background Anti-CGRP monoclonal antibodies and onabotulinumtoxinA have demonstrated efficacy and tolerability, the two most important migraine treatment attributes.

Design/Methods This non-interventional, cross-sectional study enrolled US adults with self-reported migraine diagnoses, who experienced ≥5 monthly migraine days, and had tried ≥2 prescription migraine treatments. A 25-minute discrete choice online survey was used to assess treatment preferences by having respondents select between two profiles that varied in attributes: speed of onset (24hr, 1wk, or 3mo), durability of prevention (wears off 1wk prior to next dose, 2wks prior to next dose, or does not wear off), mode of administration (IV, self-injection, or cranial injections), administration setting (at-home or in-office), and dosing frequency (1mo or 3mo). Hierarchical Bayes modeling estimated attribute-level preference weights. A latent class analysis identified subgroups that differed in their preferences.

Results 604 patients were analyzed. Mode of administration, durability of prevention, and speed of onset had the highest relative importance; administration setting and frequency of dosing had the lowest. Four groups with differing preferences were identified: those preferring auto-injection (n=128, 21%); those averse to cranial injections (n=189, 31%); those preferring faster speed of onset (n=158, 26%); and those preferring longer durability and clinicians to administer treatment (n=129, 21%). Except for those preferring auto-injection, all groups were willing to accept IV administration to achieve other treatment goals, indicating that three-fourths of participants were not averse to IV infusion as a route of administration.

Conclusions

Among people living with migraine who have ≥5 monthly migraine days, important attributes of preventive migraine treatment were mode of administration, durability of effect, and speed of onset. Infusion as a route of administration was not considered a barrier for most patients.

Authors/Disclosures
Neha Kapur PRESENTER	Neha Kapur has received personal compensation for serving as an employee of Lundbeck. An immediate family member of Neha Kapur has stock in Doordash.
Todd J. Schwedt, MD, FAAN (Mayo Clinic)	Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Schwedt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Salvia. Dr. Schwedt has or had stock in Nocira.Dr. Schwedt has or had stock in Allevalux. The institution of Dr. Schwedt has received research support from National Institutes of Health. The institution of Dr. Schwedt has received research support from United States Department of Defense. The institution of Dr. Schwedt has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Schwedt has received research support from Henry Jackson Foundation. The institution of Dr. Schwedt has received research support from Pfizer. The institution of Dr. Schwedt has received research support from National Headache Foundation. The institution of Dr. Schwedt has received research support from American Heart Association. The institution of Dr. Schwedt has received research support from AbbVie. The institution of Dr. Schwedt has received research support from Flinn Foundation. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received publishing royalties from a publication relating to health care.
Ashley Martin (Cerner Enviza)	No disclosure on file
Steven Kymes	Steven Kymes has received personal compensation for serving as an employee of Lundbeck. Steven Kymes has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Ophthalmology. Steven Kymes has received research support from Emmes Corporation.
	No disclosure on file
Xin Ying Lee (Lundbeck A/S)	No disclosure on file
Roger Cady, MD (RK Consulting, LLC)	Dr. Cady has received personal compensation for serving as an employee of Lundbeck. Dr. Cady has stock in Alder Biopharmaceutical.
Divya Asher	Divya Asher has received personal compensation for serving as an employee of Lundbeck. Divya Asher has received personal compensation for serving as an employee of AbbVie.
Meghana Karnik-Henry, PhD	Meghana Karnik-Henry has received personal compensation for serving as an employee of Lundbeck.
	No disclosure on file
	No disclosure on file
	No disclosure on file